Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia

Pathology oncology research: POR

article

Helbig, Grzegorz¹  Markiewicz, Mirosław¹  Chromik, Karolina¹  Woźniczka, Krzysztof¹  Kopińska, Anna J.¹  Boral, Kinga¹  Dworaczek, Martyna¹  Koclęga, Anna¹  Armatys, Anna¹  Panz-Klapuch, Marta¹ 

[1] School of Medicine in Katowice, Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia

关键词: Azacitidine;    Myelodysplastic syndrome;    Chronic myelomonocytic leukemia;    Acute myeloid leukemia;    Results;   

DOI  :  10.1007/s12253-018-00574-0

来源: Springer

【 摘 要 】

The administration of azacitidine (AZA) was found to be more effective than conventional care regimen (CCR) in patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) with lower blast count. We designed a study to determine efficacy and safety of AZA therapy in “real life” patients with MDS, CMML and AML. The study included 83 patients (65% male) with a median age at diagnosis of 68 years. 43 patients were diagnosed with higher-risk MDS, 30 had AML and 10-CMML. Median AZA dose was comparable between treated groups. AZA dose reduction was required for 44% of MDS, 17% of AML and 25% of CMML patients. Complete remission (CR) was achieved in 14% of MDS, 7% of AML and 10% of CMML patients. Overall response rate was following: 27% for MDS, 20% for AML and 20% for CMML. Estimated OS at 12 months was 75% for MDS, 60% for AML and 75% for CMML. Median follow-up for MDS/AML/CMML from AZA initiation to last follow-up was 9.0, 9.4 and 9.4 months, respectively. The most common toxicity of AZA therapy was myelosuppression and infections. AZA treatment was effective in a limited number of patients with acceptable safety profile.

【 授权许可】

Unknown